Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$6.83 -3.3%	$4.45	$1.38 ▼ $18.74	$187.26M	1.51	735,776 shs	1.62 million shs
ATHA Athira Pharma	$0.40 -7.5%	$0.31	$0.22 ▼ $3.67	$15.71M	2.99	1.59 million shs	210,942 shs
DBVT DBV Technologies	$10.58 -2.1%	$9.63	$2.20 ▼ $12.78	$289.68M	-0.59	191,203 shs	11,334 shs
DTIL Precision BioSciences	$4.64 +4.3%	$4.80	$3.61 ▼ $11.09	$51.46M	1.43	227,308 shs	179,848 shs
JNCE Jounce Therapeutics	$1.88	$1.89	$0.58 ▼ $5.87	$98.94M	0.75	2.46 million shs	169,314 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	0.00%	+19.06%	+50.21%	+296.63%	-54.74%
ATHA Athira Pharma	0.00%	+31.36%	+43.03%	+67.36%	-86.90%
DBVT DBV Technologies	0.00%	-6.40%	+18.68%	+38.64%	+170.00%
DTIL Precision BioSciences	0.00%	+1.71%	-9.18%	-0.22%	-56.07%
JNCE Jounce Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGEN Agenus	4.3154 of 5 stars	3.2	4.0	0.0	4.6	2.5	1.7	0.6
ATHA Athira Pharma	3.495 of 5 stars	3.0	5.0	0.0	0.0	2.7	2.5	1.3
DBVT DBV Technologies	4.0078 of 5 stars	4.4	5.0	0.0	0.0	2.3	2.5	0.6
DTIL Precision BioSciences	4.2893 of 5 stars	3.5	1.0	0.0	4.6	3.1	1.7	1.3
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGEN Agenus	2.33	Hold	$14.00	104.98% Upside
ATHA Athira Pharma	2.00	Hold	$11.25	2,696.42% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	39.47% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	912.93% Upside
JNCE Jounce Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest DTIL, AGEN, ATHA, DBVT, and JNCE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/4/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$4.00 ➝ $6.00
6/4/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/13/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $4.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGEN Agenus	$99.52M	1.88	N/A	N/A	($13.06) per share	-0.52
ATHA Athira Pharma	N/A	N/A	N/A	N/A	$1.16 per share	N/A
DBVT DBV Technologies	$4.15M	69.80	N/A	N/A	$1.42 per share	7.45
DTIL Precision BioSciences	$68.70M	0.75	N/A	N/A	$6.87 per share	0.68
JNCE Jounce Therapeutics	$82M	1.21	N/A	N/A	$3.54 per share	0.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGEN Agenus	-$227.21M	-$8.67	N/A	N/A	N/A	-196.12%	N/A	-82.33%	8/6/2025 (Estimated)
ATHA Athira Pharma	-$96.94M	-$2.07	N/A	N/A	N/A	N/A	-142.99%	-106.40%	7/30/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
DTIL Precision BioSciences	$7.17M	-$2.01	N/A	N/A	N/A	-42.99%	-69.26%	-29.30%	7/30/2025 (Estimated)
JNCE Jounce Therapeutics	-$50.92M	-$2.56	N/A	N/A	N/A	N/A	-30.90%	-26.31%	N/A

Latest DTIL, AGEN, ATHA, DBVT, and JNCE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ATHA Athira Pharma	-$0.18	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	N/A	N/A	N/A	$6.27 million	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.28	N/A	N/A	N/A	$0.64 million	N/A
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/12/2025	Q1 2025	AGEN Agenus	-$1.61	-$1.03	+$0.58	-$1.03	$26.38 million	$24.07 million
5/9/2025	Q1 2025	ATHA Athira Pharma	-$0.20	-$0.23	-$0.03	-$0.23	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
ATHA Athira Pharma	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGEN Agenus	N/A	0.11	0.11
ATHA Athira Pharma	N/A	7.26	7.26
DBVT DBV Technologies	N/A	0.72	0.72
DTIL Precision BioSciences	0.45	6.62	6.62
JNCE Jounce Therapeutics	N/A	8.37	8.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGEN Agenus	61.46%
ATHA Athira Pharma	57.12%
DBVT DBV Technologies	71.74%
DTIL Precision BioSciences	37.99%
JNCE Jounce Therapeutics	80.66%

Insider Ownership

Company	Insider Ownership
AGEN Agenus	5.50%
ATHA Athira Pharma	19.80%
DBVT DBV Technologies	1.44%
DTIL Precision BioSciences	4.00%
JNCE Jounce Therapeutics	6.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGEN Agenus	440	27.42 million	25.91 million	Optionable
ATHA Athira Pharma	40	39.04 million	31.31 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
DTIL Precision BioSciences	200	11.09 million	10.64 million	No Data
JNCE Jounce Therapeutics	137	52.63 million	48.99 million	Optionable

DTIL, AGEN, ATHA, DBVT, and JNCE Headlines

Recent News About These Companies

Philly Nonprofit Jounce Partners Helps Teachers Unlock Their Students’ Full Potential

February 17, 2025 | msn.com

Taboola Partners with Jounce Media to Verify Ad Inventory is Free From Made for Advertising (MFA) Properties

October 2, 2024 | markets.businessinsider.com

AdLib Media Group and Jounce Media Partner

August 14, 2024 | destinationcrm.comD

Jounce Therapeutics gets grant for monoclonal antibody for treating cancer by binding PD-1

April 15, 2024 | pharmaceutical-technology.comP

Multimatic Jounce Control Dampers Now Available For Chevy Colorado ZR2

April 13, 2024 | gmauthority.comG

2024 Jeep Gladiator Mojave Keeps On Truckin'

April 8, 2024 | caranddriver.comC

San Diego VC, OrbiMed make competing buyout offers for struggling Theseus

November 27, 2023 | bizjournals.com

Jounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply Source

September 19, 2023 | tmcnet.com

Kargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce Media

September 18, 2023 | finance.yahoo.com

Mediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce Media

September 5, 2023 | tmcnet.com

Board Member at Jounce Therapeutics Exercises Options Worth $324K

May 5, 2023 | benzinga.com

Board Member at Jounce Therapeutics Exercises Options Worth $172K

May 4, 2023 | benzinga.com

Jounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock Options

May 4, 2023 | benzinga.com

Jounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock Options

May 4, 2023 | benzinga.com

Jounce Therapeutics Announces Closing of Tender Offer

May 3, 2023 | finance.yahoo.com

JNCE Jounce Therapeutics, Inc.

April 29, 2023 | seekingalpha.com

The past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitable

April 17, 2023 | finance.yahoo.com

What is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?

March 29, 2023 | benzinga.com

JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders

March 27, 2023 | markets.buffalonews.comM

Buyout Offer Sends Jounce Jumping 20%

March 27, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
SoundHound Rises as Short Sellers Exit and AI Demand Grows
By Thomas Hughes | July 9, 2025
View SoundHound Rises as Short Sellers Exit and AI Demand Grows
Value vs Growth Ratio Hits Cycle Low—Top Value Picks to Buy
By Gabriel Osorio-Mazilli | June 30, 2025
View Value vs Growth Ratio Hits Cycle Low—Top Value Picks to Buy
These 3 Undervalued Stocks Could Surge as Value Rotation Nears
By Gabriel Osorio-Mazilli | July 14, 2025
View These 3 Undervalued Stocks Could Surge as Value Rotation Nears
Regional Bank Buybacks: 5 Institutions Making Big Moves
By Leo Miller | June 24, 2025
View Regional Bank Buybacks: 5 Institutions Making Big Moves

DTIL, AGEN, ATHA, DBVT, and JNCE Company Descriptions

Agenus NASDAQ:AGEN

$6.83 -0.23 (-3.26%)

Closing price 04:00 PM Eastern

Extended Trading

$6.74 -0.09 (-1.32%)

As of 07:58 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Athira Pharma NASDAQ:ATHA

$0.40 -0.03 (-7.47%)

Closing price 04:00 PM Eastern

Extended Trading

$0.39 -0.01 (-2.31%)

As of 07:46 PM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

DBV Technologies NASDAQ:DBVT

$10.58 -0.22 (-2.07%)

Closing price 03:59 PM Eastern

Extended Trading

$10.55 -0.03 (-0.25%)

As of 04:54 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Precision BioSciences NASDAQ:DTIL

$4.64 +0.19 (+4.27%)

Closing price 04:00 PM Eastern

Extended Trading

$4.57 -0.07 (-1.51%)

As of 05:22 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Jounce Therapeutics NASDAQ:JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time